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features 64 health states for every combination of study/nonstudy eye, and a health 
state representing death, derived from the VIVID/VISTA-DME and RESTORE/REVEAL 
studies. Economic inputs were based on the experts’ opinions.2 The primary and 
secondary endpoints for the study were life years gained and quality-adjusted life 
years (QALY), and years with 1 eye blind, respectively. Incremental cost-effectiveness 
ratios (ICER) were calculated per QALY and years with 1 eye blind. Analyses were 
conducted from the payer perspective and time horizon was lifetime. All costs were 
calculated in Turkish Lira (TL). Results: Total annual costs associated with IVT-AFL 
and ranibizumab were 15,315 and 14,791 TL, respectively. QALYs were 7.343 with 
IVT-AFL and 7.295 ranibizumab. According to the results of the analysis, IVT-AFL 
is a cost effective treatment option when compared with ranibizumab at a cost-
effectiveness threshold of 26,415 TL (calculated threshold from developing country 
defined as 3-fold of annual income per capita, per the World Health Organization). 
The ICER of IVT-AFL versus ranibizumab was 10,866 TL/QALY. Years with 1 eye blind 
were 0.416 with IVT-AFL and 0.647 with ranibizumab, with a difference of 0.231 year 
in favor of IVT-AFL, giving an ICER of 2268 TL/years with 1 eye blind. ConClusions: 
IVT-AFL may be a cost-effective treatment option when compared with ranibizumab 
for treatment of DME in Turkey.
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objeCtives: to assess the cost-effectiveness of twice daily (TD) 10 μ g exenatide 
with insulin glargine (EXE) vs once-daily (QD) liraglutide 1.2 mg or 1.8 mg both 
with insulin detemir (LIRA 1.2 or LIRA 1.8) in patients with type 2 diabetes mellitus 
(T2DM). Methods: the Exenatide Cost-Effectiveness Model, a validated computer 
simulation model, was adapted to the Russian healthcare setting. Patient and inter-
vention effects data were gathered from a clinical trials (Scott et al 2013, Buse et 
al 2011), comparing QD LIRA 1.2 mg, 1.8 mg and EXE 10 μ g TD, as add-on to insulin 
glargine or detemir. The full costs were calculated for 1-st line therapy, based on 
published and local sources (2014). This includes the costs of drug acquisition as well 
as appropriate inpatient, outpatient and primary care management costs (associ-
ated with maintenance and events). In this study we simulated disease progres-
sion and treatment effects per cohort 1,000 patients for 10 years period. Results: 
over a simulation period, treatment with EXE vs LIRA 1.2 drove a mean increase in 
discounted quality-adjusted life expectancy of 0.1 (0.008; 0.015) quality-adjusted 
life years (QALYs), whereas therapy with EXE vs LIRA 1.8 decrease of 0.1 (-0.018; 
-0.011) QALYs. When compared with LIRA 1.2, EXE was the dominant strategy, i.e. 
less costly (-$484) and more effective. When compared to LIRA 1.8, EXE was less 
costly (-$1,500), but less effective. The incremental cost-effectiveness ratio (ICER) 
for LIRA 1.8 vs EXE was estimated at $100,941 per QALY gained, that more greater 
than willingness-to-pay (WTP) threshold for Russia in 2014 $36,373. In this case 
more cost-effective strategy was EXE with insulin glargine. ConClusions: at a 
WTP threshold of $36,373/QALY exenatide is likely to be a cost-effective option for 
the treatment of T2DM in a Russian setting.
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objeCtives: Key challenges in the adequate management of type 2 diabetes include 
maintaining glycemic control whilst minimizing the risk of hypoglycemia, without 
increasing body weight. Glucagon-like peptide-1 (GLP-1) receptor agonists provide 
a multi-factorial approach to treatment, compared with traditional glucocentric 
approaches. The present analysis aimed to compare the cost-effectiveness of GLP-1 
receptor agonists for the treatment of diabetes in the UK. Methods: Changes in 
glycated hemoglobin, blood pressure and body mass index upon initiation of liraglu-
tide 1.2mg, exenatide BID and lixisenatide were taken from a network meta-analysis 
of 13 randomized controlled trials evaluating the efficacy and safety of GLP-1 recep-
tor agonists for the treatment of patients with type 2 diabetes uncontrolled on oral 
antidiabetic drugs. Patient lifetime projections of clinical outcomes and direct costs 
(taken from published UK-specific sources, 2013 GBP) were made in a cohort based 
on the LEAD-6 trial using a published and validated diabetes model. Outcomes 
were discounted at 3.5% annually. Sensitivity analyses were performed. Results: 
Liraglutide was associated with improved quality-adjusted life expectancy versus 
exenatide (9.17 versus 9.16 quality-adjusted life years [QALYs]) and lixisenatide 
(9.17 versus 9.12 QALYs). Improvements were driven by improved glycemic control, 
leading to a reduced incidence of diabetes-related complications. Liraglutide was 
associated with reduced costs versus exenatide (GBP37,520 versus GBP37,607) with 
cost savings as a result of avoided diabetes-related complications entirely offset-
ting increased acquisition costs. Versus lixisenatide, liraglutide was associated with 
increased costs (GBP37,520 versus GBP37,126), driven by increased acquisition costs 
which were partially offset by reduced costs of treatment of complications. Based 
on the projected outcomes, liraglutide was found to be dominant over exenatide 
and associated with an incremental cost-effectiveness ratio of GBP7,367 per QALY 
gained versus lixisenatide. ConClusions: Liraglutide 1.2mg is likely to be con-
sidered cost-effective or cost-saving versus alternative GLP-1 receptor agonists for 
treatment of diabetes in the UK.
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healthcare costs or all-cause medical costs in either sample. ConClusions: This 
real-world study suggests that short-term weight loss is associated with attain-
ment of HbA1c< 7 levels and decreased diabetes-related costs in obese population 
with no prior CVD over subsequent 12 months.
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objeCtives: Type 2 diabetes mellitus (DM) represents an important public health 
issue and it is responsible for a significant epidemiologic and economic burden. A 
cost consequence analysis (CN), aimed at assessing the economic impact of sitaglip-
tin (SITA), compared with sulfonylureas –SU (as second line therapy- add on to met-
formin) was peformed on the basis of the value based pricing approach. Methods: 
A CN of SITA vs SU (glibenclamide5mg) was carried out, on a cohort of 1000 diabetic 
patients, from both the Lombardy Regional Health Service (RHS) and societal per-
spectives by considering 12 and 36 months time horizons. Direct (drug, automonitor-
ing glycemic control, visits, hypoglicaemic- HYPOS- and CV events, and durability 
costs) and indirect costs have been considered. Epidemiologic and effectiveness 
data have been collected through available literature, trials and meta-analyses. 
Economic data have been retrieved through local/regional sources, tariffs and 
from available literature. Results: The CN analysis shows that SITA+metformin 
vs glibenclamide+metformin represents a cost saving alternative, over 3 years 
time horizon, as higher drug costs of SITA are offset by : - lower glycemic control, 
complications and durability costs resulting in a saving of almost € 9.000 from RHS 
perspective - lower productivity loss related to major cardiovascular and to HYPOS, 
leading to a saving of about € 100.000 from societal perspective. Also, SITA vs SU 
would provide, from both perspectives, -236 not severe and -54 severe HYPOS and 
-14 CV events. The analysis performed over 12 months time horizon shows that 
SITA+metformin represents a sustainable alternative from both RHS and societal 
perspectives, by leading to a saving in terms of HYPOS 136 (118 not severe and 18 
severe) and 7 CV events. ConClusions: The analysis performed shows that SITA 
represents a sustainable and cost saving alternative for the management of type 2 
DM from both clinical and economic perspectives in Lombardy.
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objeCtives: Exenatide 2mg once-weekly (EQW) is a glucagon-like peptide-1 
receptor agonist (GLP-1 RA). The objective was to assess the cost-effectiveness 
of EQW compared to the GLP-1 RAs dulaglutide 1.5mg QW, liraglutide 1.2mg 
and 1.8mg once-daily (QD), and lixisenatide 20ug QD for the treatment of adult 
patients with type 2 diabetes mellitus (T2DM) not adequately controlled on met-
formin. Methods: This analysis utilized the Cardiff Model, a previously pub-
lished T2DM disease model. Treatment effects were from a network-meta-analysis. 
Quality-adjusted life years (QALYs) were calculated, with health-state utilities 
applied to weight changes, hypoglycemia, and T2DM-related complications. Costs 
(British pounds, £) included medication and T2DM-related complications. The 
model was run over a 40-year time horizon. Costs and QALYs were discounted at 
3.5% annually. Probabilistic sensitivity analysis (PSA) was performed. Results: 
In all comparisons, EQW was associated with a QALY gain per patient; 0.046 (95% 
confidence interval [CI]: 0.036; 0.056) versus dulaglutide 1.5mg; 0.102 (95% CI: 0.093; 
0.112) versus liraglutide 1.2mg; 0.043 (95% CI: 0.034; 0.053) versus liraglutide 1.8mg; 
and 0.074 (95% CI: 0.064; 0.083) versus lixisenatide 20ug. Cost per patient was lower 
for EQW than for dulaglutide 1.5mg (-£885; 95% CI: -£942; -£827) and liraglutide 
1.8mg (-£2,085; 95% CI: -£2,143; -£2,028). EQW was therefore projected to dominate 
(i.e, lower costs and QALYs gained) dulaglutide 1.5mg and liraglutide 1.8mg. The 
cost difference per patient between EQW and liraglutide 1.2mg and EQW and 
lixisenatide 20ug was £103 (95% CI: £46; £160) and £918 (95% CI: £861; £975), respec-
tively. Cost per QALY gained with EQW versus liraglutide 1.2mg and lixisenatide 
20ug was £1,004 and £12,440, respectively. In the PSA, the probability that EQW 
is cost-effective ranged from 76-99% across all comparisons, at a willingness-to-
pay threshold of £20,000 per QALY gained. ConClusions: Results suggest that 
exenatide 2mg once-weekly is a cost-effective therapeutic option for the treatment 
of T2DM in adults inadequately controlled on metformin alone.
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objeCtives: IVT-AFL is indicated for the treatment of visual impairment due to 
DME. The objective of this analysis was to evaluate the CE of IVT-AFL compared with 
ranibizumab in DME in Turkey. Methods: The CE model is a Markov state transi-
tion model that has 3 separate phases (efficacy, maintenance, rest of life) chosen to 
adequately reflect the typical vision changes in a treated DME patient. The model 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A607
changes in treatments’ effect on weight and HbA1c, and in utility values related to 
weight changes. Dapagliflozin’s higher health benefits and cost savings are mainly 
explained by its greater beneficial effect on weight, leading to higher QALYs and less 
drug costs for dapagliflozin patients. The lower treatment costs are related to the 
insulin treatment costs (i.e. subsequent line regimens) due to the lower weight of 
dapagliflozin patients observed over time, which eventually leads to lesser insulin 
dosage. ConClusions: Dapagliflozin is a cost-saving strategy with higher health 
benefits compared to DPP4, added to metformin, for Turkish T2DM patients inad-
equately controlled on metformin mono-therapy.
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meLLiTus
Henriksson M1, Jindal R2, Sternhufvud C3, Sörstadius E3, Bergenheim K3, Willis M4
1Linköping University, Linköping, Sweden, 2Paraxel International, Chandigarh, India, 
3AstraZeneca, Mölndal, Sweden, 4The Swedish Institute for Health Economics, Lund, Sweden
objeCtives: Economic modelling in type 1 diabetes mellitus (T1DM) is complex and 
continuously evolving. The aim of this systematic review was to assess methodologi-
cal capabilities of T1DM models. Methods: A systematic search was undertaken 
in MEDLINE®, Embase®, and the Cochrane library to identify economic evaluation 
models in T1DM (English language until November 2014). The websites of HTA bod-
ies in England, Canada, Australia, France, Germany, Scotland and Spain were also 
screened. Study inclusion was based on a pre-specified protocol and carried out by a 
team of reviewers and information scientists independently, and data was extracted 
focusing on methodological capabilities. Results: 74 publications describing 13 
unique models were identified. Most models employed a Markov structure, and 
all included microvascular complications while five included both microvascu-
lar and macrovascular complications. Patient-level (microsimulation) and cohort 
approaches were equally common. While naturally varying across models, the risk 
equations that simulated event rates were generally based on a small set of studies 
which are now more than 20 years old. Treatment-effects were simulated in several 
ways; the more comprehensive models used surrogate risk factors (mostly HbA1c) to 
modify the risk of complications, but other approaches included directly modifying 
complication rates, quality-of-life, and/or resource use. The most common adverse 
events included in the models were hypoglycemia and ketoacidosis. Although the 
details provided varied, five models explicitly reported probabilistic sensitivity 
analysis capabilities. ConClusions: There was considerable heterogeneity in 
the models, likely driven by varying intended uses. The sub-set of models clearly 
intended for cost-effectiveness applications used more sophisticated approaches to 
capturing uncertainty and were among the most comprehensive, tending to include 
both micro- and macrovascular outcomes and common treatment-related adverse 
events. These models are likely to provide the most useful set of model capabilities 
despite relying on aging risk equations.
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objeCtives: To estimate the cost-effectiveness of using CANA versus DAPA or EMPA, 
three agents that inhibit sodium glucose co-transporter 2 (SGLT2), as monotherapy 
from the UK NHS perspective. Methods: The validated ECHO-T2DM model was 
used to estimate 40-year outcomes and costs associated with using CANA 100 or 
300mg versus DAPA 10mg or EMPA 25mg. Data from a 26-week network meta-analysis 
(NMA) performed to support a NICE multiple technology assessment were used to 
populate the model with treatment effects for HbA1c, blood pressure, weight and rates 
of hypoglycaemic events (hypoglycaemia data for EMPA were not possible to report 
from the NMA). Changes in lipids and rates of adverse events (AEs) associated with 
SGLT2 inhibition (i.e., urinary tract infections, genital mycotic infections) were sourced 
from a CANA monotherapy trial; values for DAPA and EMPA were assumed the same 
as CANA 100mg (as was the hypoglycaemia rate for EMPA). Sensitivity analyses were 
also performed. Results: In the base case, CANA 100mg dominated DAPA and EMPA 
with quality-adjusted life-year (QALY) gains of 0.033 and 0.015 and lower total costs of 
£69 and £3. CANA 300mg versus DAPA provided an estimated QALY gain of 0.075 and 
increased cost of £709, resulting in an incremental cost-effectiveness ratio (ICER) of 
£9,429. Versus EMPA, the ICER was slightly higher (£13,491), but still below the gener-
ally accepted threshold in the UK, with a QALY gain of 0.056 and an increased cost 
of £761. Sensitivity analyses supported these base case findings. ConClusions: 
Through an insulin-independent mechanism of action, agents that inhibit SGLT2 
improve glucose levels, blood pressure, and weight, with a low inherent risk of hypo-
glycaemia. These results suggest that both CANA 100 and 300mg are likely to be 
cost-effective monotherapy options versus DAPA and EMPA in the UK.
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objeCtives: Gestational diabetes mellitus (GDM) is associated with elevated risk 
of severe perinatal complications and type 2 diabetes (T2DM). Screening and inter-
vention is recognized as an effective way to reduce these risks. The prevalence rate 
of GDM was as high as 17.5% in China, which caused a huge economic burden. 
GDM screening and intervention was reported in many hospitals in China, however, 
lacking evaluation from an economic perspective up to now. The objective was 
to estimate the long-term cost-effectiveness associated with GDM screening in 
the urban Chinese setting to provide economic evidence for clinical practice and 
1National School of Public Health, Athens, Greece, 2Athens University Medical School, Athens, 
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objeCtives: To evaluate the long-term cost-effectiveness of dapagliflozin versus 
a sulfonylurea (SU) or a dipeptidyl-peptidase-IV (DPP-4) inhibitor, when added to 
metformin, in Type 2 diabetes mellitus (T2DM) patients inadequately controlled on 
metformin in Greece. Methods: The published and validated CARDIFF diabetes 
model, a lifetime micro-simulation model, was adapted to the Greek health care 
setting to determine the incidence of micro- and macro-vascular complications 
and diabetes-specific and all-cause mortality. Clinical inputs were derived from a 
52-week randomized clinical trial and a network meta-analysis comparing dapa-
gliflozin with SU and DPP-4 inhibitor, respectively, in combination with metformin. 
Local unit costs and utility data were retrieved from literature and assigned to model 
parameters to calculate total quality-adjusted life years (QALYs) and total costs as 
well as incremental cost-effectiveness ratios (ICERs).The analysis was conducted 
from the perspective of a third-party payer in Greece. Uncertainty surrounding 
important model parameters was explored with probabilistic sensitivity analysis 
(PSA). Results: Over a patient’s lifetime, dapagliflozin was associated with 0.488 
(95% CI: 0.477-0.5) and 0.042 (95% CI: 0.03-0.054) incremental QALYs compared 
with SU and DPP-4 inhibitor, respectively, at additional costs of € 5,149 (95% CI: 
€ 5,026-€ 5,272) and € 755 (95% CI: € 636-€ 874), respectively. These findings were mainly 
driven by the beneficial effect of dapagliflozin on weight, and its higher drug acqui-
sition costs. The corresponding ICERs were € 10,545 and € 17,871 per QALY gained 
versus the treatment with SU and DPP-4, respectively. At the defined willingness-
to-pay threshold of € 34,000 per QALY gained, PSA results showed that treatment 
with dapagliflozin was estimated to have a 99% and 57.5% probability of being cost-
effective relative to the SU and DPP-4 treatments. ConClusions: Dapagliflozin in 
combination with metformin was shown to be a cost-effective treatment alterna-
tive for patients with T2DM whose metformin regimen does not provide sufficient 
glycemic control in the current Greek health care setting.
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objeCtives: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 
receptor (GLP-1) agonist, for the treatment of type 2 diabetes mellitus (T2DM). 
The objective of this analysis was to estimate the cost-effectiveness of dulaglu-
tide versus liraglutide 1.8mg and liraglutide 1.2mg for the treatment of T2DM in 
Sweden. Methods: The IMS CORE Diabetes Model (CDM), a validated simula-
tion model, was used to estimate expected costs and outcomes. The compara-
tors investigated were liraglutide 1.8mg and liraglutide 1.2mg. In accordance 
with Swedish guidelines the analysis was conducted using a societal perspective 
including Swedish-specific direct and indirect costs over a lifetime time horizon. 
Comparative safety and efficacy data were derived from direct comparison of 
dulaglutide 1.5mg versus liraglutide 1.8mg from the AWARD-6 trial and from a 
network meta-analysis for the comparison of dulaglutide 1.5mg versus liraglutide 
1.2mg. One-way and probabilistic sensitivity analyses were conducted to explore 
the sensitivity of the model to plausible variations in key parameters and over-
all uncertainty. Results: Under base case assumptions, dulaglutide 1.5mg was 
found to be less costly and more effective versus liraglutide 1.8mg (total costs 
1,032,258 SEK vs 1,045,927 SEK; total QALYS 8.062 vs 8.033 for dulaglutide 1.5mg 
and liraglutide 1.8mg, respectively) and liraglutide 1.2mg (total costs 1,048,832 SEK 
vs 1,051,224 SEK; total QALYs 8.016 vs 7.974 for dulaglutide 1.5mg and liraglutide 
1.2mg, respectively). One-way sensitivity analyses demonstrated that dulaglutide 
1.5mg remained dominant versus liraglutide 1.8mg given plausible variations in 
key input parameters. Results of the probabilistic sensitivity analysis were con-
sistent with base case results. ConClusions: In the base case, the model found 
that dulaglutide 1.5mg was more effective and less costly than liraglutide 1.8mg 
and liraglutide 1.2mg for the treatment of T2DM in Swedish setting. Findings were 
robust to plausible variations in inputs. The introduction of dulaglutide 1.5mg may 
result in societal cost savings.
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objeCtives: Dapagliflozin, a sodium-glucose-transporter-protein-2 (SGLT2) inhibi-
tor, can serve as a treatment for type 2 diabetes mellitus (T2DM) in patients inad-
equately controlled on metformin mono-therapy. The relative health benefits and 
costs of dapagliflozin compared to a dipeptidyl-peptidase-4 inhibitor (DPP4), added 
to metformin, were assessed through a cost-effectiveness analysis (CEA) from a 
Turkish payer perspective. Methods: For the current CEA, a micro-simulation 
disease model (CARDIFF) was used. Clinical inputs were derived from a system-
atic review and network meta-analysis, along with a long-term follow-up study 
for dapagliflozin. In addition, Turkish specific cost data were collected and applied. 
The model predicted micro-and macro-vascular complications based on the UKPDS 
equations. Total Quality-Adjusted-Life-Years (QALYs) and costs were calculated over 
a lifetime horizon. Deterministic, probabilistic sensitivity analyses and elaborate 
scenario analyses were performed. Results: Compared to DPP4, dapagliflozin 
was associated with an incremental benefit of 0.590 QALYs (95% CI: 0.038; 1.232) 
and cost savings of TRY 494 (95% CI: TRY-1,727; TRY 889). Results were sensitive to 
